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A B S T R A C T
Chronic inflammation has arised as a major underlying cause of atherosclerosis, obesity and diabetes. It is mediated
by cells of innate immune system like macrophages but also by their antecedents, circulating monocytes. Roles of mono-
cyte subsets and different markers of monocyte activation in the context of metabolic disorders have been reviewed. Ap-
plying cell based approach through flow cytometry in this field has resulted with new understanding of pathophysiologic
mechanisms. Possible implications of these insights in diagnosis, prognosis and revealing of therapeutic targets in meta-
bolic disorders remain a challenge for future.
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Introduction
Chronic inflammation has arised as a major underly-
ing cause of atherosclerosis, obesity and diabetes, most
important contemporary metabolic disorders that direct-
ly contribute to development of cardiovascular diseases1.
Inflammatory processes in atherogenesis have been in-
volved from endothelial activation to the rupture of the
atherosclerotic plaque. Recent years have offered new in-
sights in the active role of adipose tissue as a source of
endocrine but also of many inflammatory factors2. More-
over, chronic inflammation preceeds insulin resistance
and in that way it has been suggested to be a crucial link
between obesity and atherosclerosis3.
Innate Immunity in Metabolic Disorders
In an effort to understand inflammatory mechanisms
in metabolic disorders, a hypothesis has been proposed
that they can be considered as disorders of the innate im-
munity. This type of immune answer is phylogenetically
older than the adaptive immunity. It is the first line of
host defense against infections and trauma and brings an
advantage in evolutional surviving in a corresponding
environment. However, when the answer is too strong,
unproportional to the offending cause or continuous (like
in overfeeding), immune overreaction could provoke ill-
ness instead of preventing it4.
Ten years ago, when Pickup et al. suggested this hy-
pothesis, they build their theory considering high level of
multiple inflammatory cytokines in metabolic disorders.
In last years, reconsidering this thesis, the attention has
been drawn to the mononuclear-phagocyte system. This
system includes macrophages, monocytes and their bone
marrow precursors, cells of the innate immunity that are
the main source of inflammatory mediators. In that con-
text, it was recently suggested that macrophages have
central role in inflammatory mechanisms of several met-
abolic diseases. Macrophages might be »at the crossroads
of insulin resistance and atherosclerosis« and monocytes
»main effectors of inflammatory actions in these disor-
ders«5,6.
The main subject of our interest, monocytes make
about 5 to 10% of peripheral leucocytes in human. Their
half-life in peripheral blood is about 3 days. Having
phagocyte and antigen presenting capabilities, monocy-
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tes take part in innate and adaptive immunity. Inflam-
matory, metabolic and immune stimuli promote recruit-
ment of monocytes in peripheral tissues where they
differentiate in macrophages and dendritic cells, although
some macrophages might also develop by local multi-
plication7.
Atherogenesis
Monocytes are the dominant inflammatory cell in-
volved in the early stages of atherogenesis. Following en-
dothelial injury, the coordinated interaction with endo-
thelial cells results in the activation and extravasation of
monocytes. This process could be divided in three basic
steps consisting of subsequent involvement of adhesion
molecules, chemokines and cytokines. The activation of
endothelial cells triggers secretion of chemokine mono-
cyte chemoattractant protein-1 (MCP-1) and attracts mo-
nocytes. MCP-1 prompts activation of monocytes by bin-
ding to its receptor CCR2. The first step of their adhesion
is rolling which is performed by a family of selectins.
Selectins allow leucocytes to weakly and reversibly bind
on endothelial cells and start the adhesion cascade. The
second step, the firm binding of monocytes occurs follow-
ing activation and interaction of integrins with their en-
dothelial ligands from immunoglobulin family, precisely
intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1). The third step is the
diapedesis of leucocytes through endothelial junctions
between cells8,9.
In atherosclerosis, from the moment of recruitment
in subendothelial space, monocytes are continuously loa-
ded with lipids by means of scavenger receptors and de-
velop into foam cells. Their accumulation builds the fatty
streaks, precursors of atherosclerotic plaques. These
cells also secrete inflammatory mediators that stimulate
proliferation and infiltration of smooth muscle cells, ma-
turing of the complex lesion and finally participate in the
rupture of the plaque and consequent thrombosis8,9.
Obesity and Insulin Resistance
The role of mononuclear-phagocyte system also emer-
ged recently in obesity and insulin resistance. Adipose
tissue in obesity undergoes multiple structural and func-
tional changes, involving adipocytes hypertrophy, switch
in adipocytokines secretion pattern but also macropha-
ges infiltration10. In fact, besides adipocytes, adipose tis-
sue contains cells of the so-called stromovascular com-
partment. Adipose tissue in thin persons contains only
about 10% of macrophages but in obesity they rise up to
40%. The expression of macrophage marker CD68 has
correlated with body mass index and this level falls with
reduction of weight, for instance after bariatric opera-
tions or with insulin sensitizing medication11,12. Studies
confirmed that 30 to 59% of enhanced genes expression
in adipose tissue in obesity are typical for macrophages.
Fluorescent sorting of cells of adipose tissue showed the
source of several key inflammatory molecules like tumor
necrosis factor a (TNFa), interleukin-1b (IL-1b) and in-
ducible nitric oxide synthase (iNOS) are macrophages
unlike other stromovascular cells and adipocytes11,12. In
experiments these cells have been shown to secrete about
90% of inflammatory adipocytokines like MCP-1 or
TNFa13. Step by step, macrophages have become the fo-
cus of the link between obesity and insulin resistance. In
vitro experiments proved that macrophages block insulin
action in adipocytes by changing expressions of glucose
transporter 4 (GLUT4) and insulin receptor supstrate-1.
Animals with disabled nuclear factor kB (NFkB) inflam-
matory path in myeloid lineage were protected from de-
veloping insulin resistance and glucose intolerance14–16.
On the other hand, animals were prone to develop these
disorders by deletion of nuclear transcription factor pe-
roxisome proliferator-activated receptor-g (PPAR-g) in
macrophages17. Although the definitive confirmation of
the causal relation between macrophages and insulin re-
sistance has been still lacking because macrophages mi-
ght have been just a bystander in this mechanism, there
is an enormous challenge to pursue further this hypo-
thesis18. Its appealing value consists in the fact that
macrophages might be possible site for intervention in
order to prevent metabolic consequences of obesity.
Monocytes and Metabolic Disorders
Macrophages in adipose tissue, just like those in arte-
rial wall, are derived from circulating monocytes origi-
nating from myeloid progenitors in bone marrow11. The
mechanism of the recruitement of monocytes to inflam-
matory tissues, their activation and differentiation in
macrophages is similar in atherosclerosis and obesity.
The specificity of atherogenesis is that this process in-
volves big arterial vessel walls and arterial shear forces,
unlike all other cases where it occurs at the capillary
level. The trigger of atherosclerosis is endothelial injury
and in obesity it has still been undetermined.
Experimental evidences prove that monocytes sub-
stantially take part in inflammatory processes of athero-
genesis and obesity but several studies demonstrated
that this reflects also on their circulation level in clinical
settings. In large prospective studies on representative
sample of American population, circulating monocytes
were related with measures of subclinical peripheral
atherosclerosis19. In asymptomatic men of medium age
statistically significant difference was found in the num-
ber of monocytes between groups divided by the body
mass index20. Recently published study in healthy sub-
jects revealed also that among leucocytes, the highest
cardiovascular risk is brought by monocytes. Although
the direct link with insulin resistance has not been inves-
tigated in this study, it could be recognized indirectly
through positive correlation of monocytes with body
mass index, waist circumference, systolic pressure, high
density lipoprotein (HDL) cholesterol and triglycerides,
components of the so-called metabolic syndrome21.
V. Pand`i} Jak{i} et al.: Monocytes in Metabolic Disorders, Coll. Antropol. 34 (2010) 1: 319–325
320
Monocyte Subsets
The more precise characterization and insight in the
functional role of monocyte was enabled by the discovery
of their heterogenous phenotype22. The specific surface
marker for monocyte population is CD14, a part of the
lipopolysacharide receptor. Based on the intensity of
CD14 expression, monocytes could be differentiated in a
large majority of cells that express high levels of CD14,
CD14++, and about 10–15% of monocytes with lower ex-
pression of CD14 surface marker, CD14+. The additional
separation of monocytes is defined by the surface expres-
sion of CD16 antigen, also known as Fc receptor gIII.
Four different subsets could be differentiated from com-
binations of these two antigens, but the two best defined
are CD14++CD16– and CD14+CD16+. CD14++CD16– sub-
set is considered as classic monocytes because it is the
closest to the original definition of monocytes as cells
that migrate to inflamed areas. The subset CD14+CD16+
seems to be more mature, to be more potent antigen pre-
senting cells and has more similarities with macropha-
ges. CD16+ monocytes are also more important source of
TNFa in the blood7,8,23,24.
In different studies high levels of CD14+CD16+ mono-
cytes have been related with states of chronic inflamma-
tion. This subset is expanded in infectious diseases like
AIDS or sepsis, but also in coronary heart disease. CD14+
CD16+ monocytes have been related with atherogenic
lipids and inversely correlated with HDL cholesterol26. In
a study with renal disease patients, levels of CD14+CD16+
cells were independently related with subclinical athero-
sclerosis measured by intima-media thickness27.
In contrast to that, another study has not found dif-
ference in the number of CD14+CD16+ cells between
groups of patients with diabetes, with diabetes and car-
diovascular disease and control group. However, the ex-
pression of CD14 on monocytes has been significantly
higher in the group with diabetes, and even higher in the
group with diabetes and cardiovascular disease. Higher
number of CD14++ monocytes has been shown in one
more study in patients with diabetes mellitus28,29. What
is the role of these different monocyte subsets in athero-
sclerosis or obesity is still to be determined.
Monocyte Activation
Further characterisation of monocyte subsets could
be assessed from the changing phenotype during the
monocyte activation and extravasation. As their interac-
tion with endothelium involves expression of adhesion
molecules, chemokine receptors, intracellular free radi-
cals or proinflammatory cytokines, this is reflected in the
different profile of functional phenotype markers. Our
aim was to present several of the most representative ex-
amples of activation markers.
For instance, different expression of chemokine re-
ceptors is also distinctive for the already mentioned
monocyte subsets. The inflammatory CD14++ subset, ex-
press high levels of CCR2, chemokine receptor for MCP-1,
low levels of CCR5, receptor of CCL3 and medium levels
of CX3CR1, receptor for fractalkine. The CD16+ subset is
CCR2 negative, but express high levels of CX3CR1 and
CCR5 receptors7.
CCR2
The key promigratory signal of MCP-1 to monocytes
is transferred by chemokine receptor CCR230. Strong re-
duction of macrophage infiltration, foam cell formation
and atherosclerosis progression was found in the model
of apoE-/- mouse with deletion of CCR231. This has con-
firmed its causal relationship with atherosclerosis on ex-
perimental level.
In studies in humans expression of CCR2 on mono-
cytes has positively correlated with levels of low density
lipoprotein (LDL) cholesterol and negatively with HDL
cholesterol32,33. However, suppression of CCR2 on mono-
cytes was found in models with high oxidized LDL choles-
terol that is usually formed in the intima of arteries34–36.
It has been considered that suppression of CCR2 stimu-
lates retention of recruited monocytes in the vessel wall
and that might represent a step in the differentiation of
monocytes to macrophages or foam cells. In the pre-
sumed two step model, this chemokine receptor first me-
diates recruitment of monocytes and then, suppressed by
oxidized LDL, promotes the pathologic accumulation of
these cells in the intima37,38.
Recent studies have shown also a role of CCR2 in the
development and maintaining of obesity. In animals fed
by high-fat diet it was determined that macrophages ex-
press higher levels of markers related to the migration of
cells like CCR239. In mouse with deletion of CCR2, the
number of macrophages in fat tissue was reduced, just as
inflammatory markers and systemic insulin resistance.
Pharmacologic CCR2 antagonist reduced the quantity of
macrophages in fat tissue and raised insulin sensitivity
in mouse with preexisting obesity. However, a study on
animals with CCR2 deficiency form different genetic
background did not show the same effect of this muta-
tion, so infiltration of macrophages might be mediated
also by CCR2 independent influences40,41.
Gene expression of CC chemokines involved in mono-
cyte chemotaxis and their receptors, particularly CCR2
was higher in subcutaneous and visceral adipose tissue of
obese patients. The expression levels of CCR2 on circula-
ting monocytes were significantly increased in diabetic pa-
tients and correlated with poor blood glucose control42,43.
According to these data, the system MCP-1/CCR2 has
probably direct role in recruitement and retention of
monocytes in fat tissue and atherosclerotic plaques44.
Exloring these contributions would probably have implia-
tions on effectivness of treatement with CCR2 antagonists.
CX3CR1
CX3CR1 is a receptor for fractalkine, a recently dis-
covered chemokine with distinctive structural and func-
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tional properties45. Fractalkine is present as membrane
bound molecule or a soluble glycoprotein. Besides being a
chemokine, fractalkine functions as an adhesion mole-
cule for monocytes. CX3CR1 is expressed on leucocytes
and fractalkine is expressed by endothelial cells in in-
flammatory conditions, but also on smooth muscle cells
and platelets. The expression of fractalkine and its recep-
tor has been also documented inside the atherosclerotic
plaque46. Experimental data confirmed decreased athero-
sclerosis in animals with CX3CR1 deletions47 and several
human studies have concluded that polymorphisms of
CX3CR1 have been related with reduced risk for athero-
sclerotic cardiovascular disease48.
Considering the surface expression of CX3CR1 on
monocytes, no difference between coronary artery dis-
ease patients and controls and no effect of statin therapy
was found in one study49 and a second suggested higher
levels of CX3CR1+ cells among peripheral blood mono-
nuclear cells, especially monocytes in coronary artery
disease patients50.
Although the role of CX3CR1 in migration of CD16+
subset of monocytes has been assumed, the precise role
of CX3CR1 in monocyte recruitment is still to be deter-
mined51. In the process of monocyte adhesion and trans-
migration CX3CR1/CX3CL1 system seems to have also
an indirect role. Experimental data show that endothe-
lial fractalkine first binds to CX3CR1 of platelets and
that increases platelet P-selectin expression. Activated
platelets then trigger monocyte adhesion51,52.
The most recent experimental study has shown that
the absence of the CX3CR1 receptor results in increased
apoptosis of monocytes and foam cells. Together with
previously described potential effects on monocyte re-
cruitment, that would lead to reduced foam cell load and
the inhibition of plaque progression53. Inhibition of
CX3CR1/CX3CL1 interaction during early atherogenesis
stages might be beneficial, however since CX3C signals
are likely to be required for foam cell survival too, such
inhibition during later atheroma stages could result in
disease exacerbation. These results suggested that possi-
ble therapeutic approach would require careful consider-
ation and profound understanding of the system53.
CD11b
Different subsets of monocytes have different expres-
sion of adhesion molecules, but in most studies adhesion
molecules were investigated independently from mono-
cyte subsets. CD11b on cell surface is a well investigated
marker of activation and monocyte adhesion. CD11b is
one of several a subunits of b2 integrin receptor CD11/
CD1828. Strong and permanent adhesion of monocytes
on endothelial cells occurs only with activation of inte-
grin. Ligand of CD11b on endothelial cells is ICAM-1.
Levels of soluble form of this endothelial adhesion mole-
cule, sICAM-1, are recognized as useful predictor of car-
diovascular events in healthy persons and related with
different stages of cardiovascular diseases. Raised levels
of endothelial adhesion molecules were found in men
with abdominal obesity54,55.
Besides studies on adhesion molecules on activated
endothelial cells important number of studies has shown
stronger expression of their receptor CD11b on mono-
cytes in pathophysiologic states that are linked with de-
velopment or advanced atherosclerosis. In several studies
raised expression of this marker was found in patients
with coronary heart disease, especially in unstable an-
gina56. Increased expression of CD11b together with CD14
was determined in patients with hypercholesterolemia,
and they were lowered with simvastatin treatment57.
Experimental studies point to the raised expression of
CD11b on circulating monocytes in obesity even before
development of diabetes and hypertension58. Higher lev-
els of CD11b and increased adhesion on endothelial cells
was shown in vitro on monocytes under the prolonged in-
fluence of free fatty acids59. Leptin also positively influ-
enced expression of CD11b on monocytes60. It was shown
that MCP-1 induces expression of CD11b on peripheral
monocytes in the model of experimental atherosclerosis
in apoE-/- mouses61. Similar direct influence of MCP-1 on
the expression of CD11b on monocytes was obtained in
the experiment with overfed mouses62.
These experimental models support strong correla-
tion of CD11b with measures of obesity but in clinical
data this relationship has not been consistently recog-
nized. In female patients with extreme obesity before
bariatric operation and a control group with normal body
mass index, there was no difference in expression of
CD11b on monocytes. In a prospective analysis, CD11b
on monocytes has not changed expression after bariatric
operation63. On the other hand, when stratified by CD11b
expression on circulating monocytes, obese hyperten-
sives had markedly increased expression of the macro-
phage marker CD68 in adipose tissue64.
Results are somehow clearer in clinical studies that
have dealed with postprandial changes on monocytes.
Raised expression of CD11b on monocytes was found af-
ter glucose load in patients with diabetes, but also in con-
trol group65. In the study that evaluated expression of
CD11b on monocytes in relation with elevated triglycer-
ides after fat meal, significant increase of CD11b was
found 6 hours postprandially66. In a different study rai-
sed expression of CD11b on monocytes was found even
10 hours after fat meal67.
Toll-like receptors
An essential step further in understanding innate in-
flammatory mechanisms was the recent discovery of
toll-like receptors (TLR). They recognize pathogen-asso-
ciated molecular patterns on exogenous pathogens like
bacteria and viruses but also on possible endogenous
ligands68–70. Being the crucial recognition and signaling
receptors in the host defense, toll-like receptors are also
linking innate and adaptive immunity71,72. The discovery
of the expression of several toll-like receptors, particularly
TLR1, TLR2 and TLR4, on endothelial cells and ma-
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crophages in atherosclerotic lesions, has implied their
critical role in atherogenesis73,74. Once again, the stron-
gest evidence for the involvement of TLR signaling has
been documented from experimental models of athero-
sclerosis prone mouse. Animals with genetic deficiency of
TLR4 had significantly reduced atherosclerotic plaque
size and macrophage infiltration75. Moreover, TLR4 poly-
morphisms that weaken the receptor function and in-
flammatory response have been associated with lower
risk for atherosclerosis and acute coronary events76,77.
Several endogenous pathways of TLR activation are
associated with metabolic disorders. TLR4 in macro-
phages was upregulated by oxidized LDL. Activation of
TLR4 by free fatty acids provided a possible inflamma-
tory mechanism that link nutrition, obesity and athe-
rosclerosis78. Expression of TLR4 in monocytes was in-
duced by high glucose and inhibited by pioglitazone79,80.
Flow cytometry analysis of circulating monocytes deter-
mined that patients with coronary artery disease and
acute coronary syndromes had increased expression of
TLR481,82. The importance of toll-like receptors consists
in the fact that their involvement for the first time sug-
gested a site where inflammatory mechanisms in athero-
sclerosis might be initiated72.
Oxidative Burst
Oxidative stress is an imbalance in oxidative-reduc-
tion processes because of overproduction of reactive oxi-
dative species (ROS) or a deficit in antioxidative activity.
Free radicals have important physiologic roles. Organ-
isms use it first of all as an antimicrobial tool in host de-
fense during phagocytosis. This event is called oxidative
burst and could be measured by various fluorescent
probes in flow cytometry. Most cells can produce small
oxidative burst under the influence of different cyto-
kines, growth factors and hormones. That has led to the
knowledge that free radicals serve as signal molecules in
various cell functions. Physiologic cell radicals are pro-
duced in controlled way and in low concentrations be-
cause their toxic capabilities limit their role as second
messengers83.
Free radicals are admitted to have important func-
tions in the pathogenesis of endothelial dysfunction and
development of atherosclerosis. Two most important me-
chanisms involve capturing of nitric oxide and oxidation
of LDL. Main site of free radicals production in vessel
wall is in endothelial, smooth muscle cells and fibro-
blasts. According to some investigations, blood cells are
also an important source of ROS, especially phagocytes,
neutrophils and monocytes. ROS easily pass membrane
and may affect other leucocytes but also the close vascu-
lar endothelium. Through the transcription factor sensi-
tive on oxidative stress, NFB, free radicals stimulate ex-
pression of adhesion molecules and chemokine receptors
on monocytes84,85.
Experimental evidence points to the oxidative burst
in mononuclear cells as one of possible pathophysiologic
mediators of chronic inflammation in atherosclerosis and
obesity. Oxidation of LDL in vitro was shown to be much
faster in obese persons than in non-obese86. Further
analysis confirmed that higher production of free radical
was located in adipose tissue and it was suggested that it
could be related with macrophage infiltration because of
their high capacity of free radical production87. In vitro
measurement confirmed stimulative effect of leptin on
oxidative burst in monocytes88.
Hyperlipidemic patients presented significantly higher
rates of monocyte ROS generation and positive correla-
tion between monocyte ROS generation and oxidized
LDL concentrations was found89. Oxidative burst in mo-
nocytes has been related with intima-media thickness as
a surrogate of atherosclerosis in patients with hyper-
tension84. Increased reactive oxygen species were de-
tected also in monocytes from obese patients suggesting
that these cells are already committed to an inflamma-
tory phenotype in peripheral blood90.
Flow Cytometry Contributions
Active role of inflammatory mechanisms in metabolic
disorders has supported a new, cell based approach in
their research. We have presented a considerable amount
of data that was provided by applying the succesful expe-
rience of flow cytometry analysis in characterizing im-
mune cells. Advantages of flow cytometry are that it of-
fers a multiparametric and dynamic understanding of
cell biology. Diversity of cell-specific markers helps in dis-
covering sequences of events in cells activation and sig-
nalling pathways. Integration of these data enables in-
sight in functions of cell systems and understanding
sources of pathophysiological processes91.
This method is inevitable in in vitro and in vivo exper-
imental studies, but interesting results have been ob-
tained by moving from the basic science to clinical appli-
cations. The challenge of possible implications in diag-
nosis, prognosis and revealing of therapeutic targets in me-
tabolic diseases remains for future. Still lacking are pro-
spective large scale studies that present the well-known
method of confirming biomarkers in metabolic diseases.
In that context the recently published flow cytometry
study in the framework of Atherosclerosis Risk in Com-
munities (ARIC) Carotid magnetic resonance imaging
study has been an important step towards this direction,
especially because it was precedeed by efforts to validate
reliability of multicenter studies in this field92,93.
Lot of data support the hypothesis that monocytes are
representative and easily accessible model to study the
inflammation in metabolic disorders and future advan-
ces in this research might provide clues to recognize the
metabolic risk even in subclinical stage94.
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MONOCITI U METABOLI^KIM POREME]AJIMA – DOPRINOSI PROTO^NE CITOMETRIJE
S A @ E T A K
Kroni~na upala smatra se temeljnim uzrokom ateroskleroze, debljine i {e}erne bolesti. Posredovana je stanicama
uro|enog imunolo{kog sustava poput makrofaga, ali isto tako i njihovim prethodnicima, monocitima u cirkulaciji. Raz-
motrili smo uloge podskupina monocita te razli~itih monocitnih aktivacijskih biljega u kontekstu metaboli~kih poreme-
}aja. Primjena metode proto~ne citometrije u tom podru~ju doprinijela je novom razumijevanju patofiziolo{kih mehani-
zama. Mogu}a zna~enja tih spoznaja u dijagnozi, prognozi i razotkrivanju terapijskih ciljeva u metaboli~kim poreme-
}ajima preostaju kao izazov u budu}nosti.
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